Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
about
Ticagrelor therapy and atrioventricular block: Do we need to worry?Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.One-year outcomes and secondary prevention in patients after acute minor stroke: results from the China National Stroke Registry.A Multicenter Cohort Comparison Study of the Safety, Efficacy, and Cost of Ticagrelor Compared to Clopidogrel in Aneurysm Flow Diverter Procedures.Single or dual antiplatelet therapy after PCI.Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint.The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease.Effects of ticagrelor in a mouse model of ischemic stroke.Clopidogrel loading dose versus maintenance dose to treat patients with acute ischaemic stroke in China (CLASS-China): results from a prospective double-blind randomised clinical trial.Medical Treatment of Intracranial Atherosclerosis: An Update.Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.Differences in relative and absolute effectiveness of oral P2Y 12 inhibition in men and women: a meta-analysis and modelling study.Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.Investigating Real-World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records.Ticagrelor - toward more efficient platelet inhibition and beyond.Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.[Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]Critical Care Management of Acute Ischemic Stroke.Autonomic Nervous System and Stress to Predict Secondary Ischemic Events after Transient Ischemic Attack or Minor Stroke: Possible Implications of Heart Rate Variability.Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study.Association of ABCB1 promoter methylation with aspirin exposure, platelet function, and clinical outcomes in Chinese intracranial artery stenosis patients.Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial.Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot).Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis.
P2860
Q33695952-1390187E-04C7-42AE-AA58-80186FDBC7ADQ38378830-5BA4A431-9C6D-4450-B240-C66E8B9A848DQ38801855-A847E9B1-F828-4856-8261-B567C4483289Q38802062-AD402EB4-FAFD-4BB2-8AE4-71689DAC8BE1Q38970275-110FE464-952E-401A-935C-F07EFA1B8415Q38980493-050C1EDE-AD17-4DDE-9697-01EFF27503A9Q39193524-410B1464-0E40-4D57-8E19-4E7F8685CD7AQ41456276-018F50CC-EC29-4D65-A3D2-D87395E5519EQ41865115-B1DCC536-EE0B-4711-AA63-BC1F68743B26Q42279148-9A25B34A-CB39-41D2-AA7F-7A0F65592D00Q42380289-3203CC10-F3F9-4302-86E0-525313C6CE11Q47254205-FE1F9551-D7B3-4701-BE51-69D44E62FFABQ47665315-D1C93F40-6964-42A4-AB61-8FA0212F80EAQ48344587-99C716D3-C3BB-4281-9970-B4A7DEFB26ECQ49222788-42F41275-DEAE-4B21-B960-C4397EFAE666Q49337303-BE7BD3EB-8098-48CE-B570-35E90B290213Q49549481-183C622E-3BA2-4DA1-B7BD-34B966D8C0FDQ50014351-9BBF56D0-4C6A-4DB1-9AD3-0FFB0155FC40Q52096569-790167DE-EF29-41E3-9D35-95103049714FQ52647773-7C0E13B6-60F9-4636-8327-35FE3EF499B0Q52682104-430C0EA7-DD3F-448A-AC07-E6A54EB37508Q53163564-9CB0F10D-9F6E-4A6A-8348-E8EB52DCEE93Q53839624-C36B4F34-5396-44CA-99B0-425264277521Q54997236-FB9E0A53-BDBA-49E2-9FDE-716E8BF6AC5CQ55708972-9279A58C-B2E1-4FF3-9793-1C5F982C80D6
P2860
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
@en
type
label
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
@en
prefLabel
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
@en
P2093
P356
P1476
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
@en
P2093
Carlos A Molina
Gregory W Albers
Hans Denison
J Donald Easton
Jenny Jonasson
K S Lawrence Wong
Kazuo Minematsu
Peter Held
Pierre Amarenco
S Claiborne Johnston
P356
10.1056/NEJMOA1603060
P407
P577
2016-05-10T00:00:00Z